<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fingolimod: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fingolimod: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fingolimod: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="16078" href="/d/html/16078.html" rel="external">see "Fingolimod: Drug information"</a> and <a class="drug drug_patient" data-topicid="16079" href="/d/html/16079.html" rel="external">see "Fingolimod: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F10824425"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gilenya;</li>
<li>Tascenso ODT</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871206"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Fingolimod;</li>
<li>APO-Fingolimod;</li>
<li>Gilenya;</li>
<li>JAMP Fingolimod;</li>
<li>MAR-Fingolimod;</li>
<li>MYLAN-Fingolimod;</li>
<li>PMS-Fingolimod;</li>
<li>SANDOZ Fingolimod;</li>
<li>TARO-Fingolimod;</li>
<li>TEVA-Fingolimod</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F12809667"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Sphingosine 1-Phosphate (S1P) Receptor Modulator</span></li></ul></div>
<div class="block dop drugH1Div" id="F51536562"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Administer the initial dose, the first dose following therapy interruption (&gt;14 days), and the first dose of a dose increase in a setting in which resources to appropriately manage symptomatic bradycardia are available; monitor for 6 hours postdose; additional monitoring may be necessary in select patients. Prior to initiating fingolimod therapy, complete all age-appropriate immunizations (particularly human papillomavirus and varicella zoster virus) according to current immunization guidelines, if possible. In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other appropriate specialists (eg, liver specialists) regarding treatment options before initiating therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31462584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31462584'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="800e2fc1-5444-4538-baf2-520898316bf7">Multiple sclerosis, relapsing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, relapsing:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents: Capsule or orally disintegrating tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">≤40 kg: Oral: 0.25 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;40 kg: Oral: 0.5 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51468281"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution in severe renal impairment (exposure is increased). A small pharmacokinetic study in adult patients with stable severe impairment (CrCl &lt;30 mL/minute) and not on dialysis suggests that increases in exposure to fingolimod and the active metabolite (fingolimod-P) are not clinically meaningful and dosage adjustment may not be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26308173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26308173'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51468282"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥10 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline hepatic impairment: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate impairment: No dosage adjustment necessary; use with caution and monitor closely.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution and closely monitor; exposure is increased.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatotoxicity during therapy: </i></p>
<p style="text-indent:-2em;margin-left:6em;">ALT &gt;3 times ULN and total bilirubin &gt;2 times ULN: Interrupt treatment; permanently discontinue fingolimod if alternative etiology for hepatic injury cannot be identified due to risk of severe drug-induced liver injury.</p></div>
<div class="block doa drugH1Div" id="F10829906"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="16078" href="/d/html/16078.html" rel="external">see "Fingolimod: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> First-dose, 6-hour monitoring is recommended for all patients; administer the first dose and doses following therapy interruption (longer than 14 days) in a setting in which resources to appropriately manage symptomatic bradycardia are available. Complete all immunizations according to current immunization guidelines, if possible, prior to initiating fingolimod therapy. In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other appropriate specialists (eg, liver specialists) regarding treatment options before initiating therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31462584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31462584'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="800e2fc1-5444-4538-baf2-520898316bf7">Multiple sclerosis, relapsing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, relapsing:</b>
<b>Oral:</b> 0.5 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991072"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution in severe renal impairment (exposure is increased). A small pharmacokinetic study in patients with stable severe impairment (CrCl &lt;30 mL/minute) and not on dialysis suggests that increases in exposure to fingolimod and the active metabolite (fingolimod-P) are not clinically meaningful and dosage adjustment may not be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26308173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26308173'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988333"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (Child-Pugh classes A and B): No dosage adjustment necessary; use with caution and monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling; use with caution and monitor closely (exposure is increased).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">ALT &gt;3 times ULN and total bilirubin &gt;2 times ULN: Interrupt treatment; permanently discontinue fingolimod if alternative etiology for hepatic injury cannot be identified due to risk of severe drug-induced liver injury.</p></div>
<div class="block adr drugH1Div" id="F10829804"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported in adults, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (11%), diarrhea (13%), nausea (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase (≤15%), increased serum alanine aminotransferase (≤15%), increased serum aspartate transaminase (≤15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (12%), sinusitis (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (3%), first-degree atrioventricular block (5%), hypertension (8%), second-degree atrioventricular block (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Actinic keratosis (2%), alopecia (3%), basal cell carcinoma of skin (2%), cutaneous papilloma (3%), tinea versicolor (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum triglycerides (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia (2%), lymphocytopenia (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes virus infection (9%), herpes zoster infection (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (2%), migraine (6%), seizure (children and adolescents: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (10%), limb pain (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (8%), dyspnea (9%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Pneumonia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Asystole, complete atrioventricular block, syncope, ventricular tachycardia (Elounais 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Malignant melanoma (Robinson 2016), Merkel cell carcinoma</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Glioblastoma (Sharim 2016), hemolytic anemia, immune thrombocytopenia (Yuen 2017), Kaposi sarcoma, malignant lymphoma (including B-cell lymphoma, CNS lymphoma, non-Hodgkin lymphoma, T-cell lymphoma [including cutaneous T-cell lymphoma and mycosis fungoides]), squamous cell carcinoma, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury (including acute hepatic failure [Biolato 2021]) (Memon 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Immune: Immune reconstitution syndrome (Piñar Morales 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection, human papilloma virus infection (including related cancer), opportunistic infection (including atypical mycobacterial infection, cryptococcosis, and JC virus infection), varicella zoster infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Herpes simplex encephalitis (Pfender 2015), progressive multifocal leukoencephalopathy (Piñar Morales 2022), reversible posterior leukoencephalopathy syndrome, status epilepticus</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Macular edema (Jasani 2017), retinal hemorrhage (Ueda 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Decreased lung function (diffusion lung capacity for carbon monoxide) (Bianco 2016), reduced forced expiratory volume (Bianco 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Multi-organ failure</p></div>
<div class="block coi drugH1Div" id="F10829511"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to fingolimod (including rash, urticaria, and angioedema) or any component of the formulation; myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or New York Heart Association class III/IV heart failure in the past 6 months; Mobitz Type II second- or third-degree atrioventricular block or sick sinus syndrome (unless patient has a functioning pacemaker); baseline QTc interval ≥500 msec; concurrent use of a class Ia or III antiarrhythmic; concurrent use with other products containing fingolimod (Tascenso ODT).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Patients at increased risk for opportunistic infections, including those who are immunocompromised due to treatment (eg, antineoplastic, immunosuppressive or immunomodulating therapies, total lymphoid irradiation, bone marrow transplantation) or disease (eg, immunodeficiency syndrome); severe active infections including active chronic bacterial, fungal, or viral infections (eg, hepatitis, tuberculosis); known active malignancy (excluding basal cell carcinoma); severe hepatic impairment (Child-Pugh class C); pregnancy and women in childbearing years not using effective contraception.</p></div>
<div class="block war drugH1Div" id="F10829524"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse reactions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Atrioventricular (AV) block: May result in transient and asymptomatic AV conduction delays, which typically resolve within 24 hours of treatment initiation; recurrence may be observed following discontinuation and subsequent reinitiation of therapy. Third-degree AV block and AV block with junctional escape occurred within the first 6 hours of the initial dose, and transient asystole and unexplained death have occurred within the first 24 hours; syncope has also occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bradycardia: Initiation must occur in a setting with resources and personnel capable of appropriately managing symptomatic bradycardia. Following the first dose, heart rate may decrease as soon as 1 hour postdose, with the maximal decrease usually occurring ~6 hours postdose with recovery (but not to baseline levels) 8 to 10 hours postdose. A second heart rate decrease occurs within 24 hours after the first dose and may be more pronounced than the first 6-hour rate decrease. Most patients are asymptomatic; however, hypotension, dizziness, fatigue, palpitations, and/or chest pain may occur; symptoms usually resolve within 24 hours. With the second dose, heart rate may also decrease, but to a lesser magnitude than observed with the first dose. Heart rate typically returns to baseline after 1 month of chronic therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reaction: Hypersensitivity reactions, including rash, urticaria, and angioedema upon treatment initiation, have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: Increased blood pressure may occur ~1 month after initiation of therapy; monitor blood pressure throughout treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: A dose-dependent decrease in lymphocyte counts may occur. Obtain a CBC, including lymphocyte count, prior to initiation of therapy, then every 3 months thereafter or as clinically indicated (AAN [Rae-Grant 2018]). Patients with lower lymphocyte counts at baseline, BMI &lt;18.5 kg/m<sup>2</sup>, females, and those with previous exposure to natalizumab may be at increased risk (Baharnoori 2018; Warnke 2014). In patients who develop lymphopenia during fingolimod treatment, using an alternate dosing schedule (eg, every other day dosing <b>or </b>dosing 5 days out of 7 days) may raise circulating lymphocyte counts without increasing disease activity (Longbrake 2018). Interrupt therapy with fingolimod in patients who develop serious infections. Due to a potential for delayed lymphocyte recovery following treatment interruption or discontinuation, monitor lymphocyte counts for at least 2 months after stopping therapy. Do not initiate or restart fingolimod in patients with acute or chronic infections.</p>
<p style="text-indent:-2em;margin-left:6em;">- Bacterial infections: Serious opportunistic bacterial infections (eg, atypical mycobacteria) have been reported with use. Promptly evaluate and treat patients with symptoms and signs of an infection.</p>
<p style="text-indent:-2em;margin-left:6em;">- Cryptococcal infections: Cases of cryptococcal meningitis and disseminated cryptococcal infections (including fatalities) have been reported. Cryptococcal infections have generally occurred after ~2 years of treatment, although may occur earlier (relationship between risk and duration of treatment is unknown). Patients with signs and symptoms of cryptococcal infections should undergo prompt diagnostic evaluation and treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">- Hepatitis: In high-risk populations, screen for latent hepatitis infections prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other specialists (eg, liver specialists) regarding treatment options before initiating therapy (AAN [Farez 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">- Herpes: Serious, life-threatening herpes infections, including fatalities (eg, disseminated primary herpes zoster and herpes simplex encephalitis) have occurred. Consider disseminated herpes infections as an etiology if an atypical multiple sclerosis (MS) relapse or multiorgan failure occurs. Cases of Kaposi sarcoma (associated with human herpes virus-8) have been reported; if suspected, prompt diagnostic evaluation and management is required.</p>
<p style="text-indent:-2em;margin-left:6em;">- Human papilloma virus: Human papilloma virus (HPV) infections, including papilloma, dysplasia, warts, and HPV-related cancer, have been reported. Cancer screening (eg, Papanicolaou [Pap] test) is recommended per standard of care. Consider HPV vaccination prior to treatment initiation.</p>
<p style="text-indent:-2em;margin-left:6em;">- Tuberculosis: In high-risk populations or in countries with high tuberculosis (TB) burden, screen for TB infection prior (latent TB) to initiating therapy. For patients who screen positive, consult infectious disease specialists regarding treatment options before initiating therapy (AAN [Farez 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">- Varicella zoster: Serious, life-threatening events of disseminated varicella infections have occurred with fingolimod use. Varicella zoster virus vaccination is recommended prior to initiation of treatment in patients without a health care professional-confirmed history of chickenpox, without a documented full course of varicella zoster vaccination, and patients who are VZV antibody negative; postpone fingolimod treatment for 1 month after varicella zoster vaccination.</p>
<p style="text-indent:-2em;margin-left:4em;">• Liver injury: Liver injury has occurred (including acute liver failure requiring liver transplant); elevated serum liver enzymes and total bilirubin have been reported as early as 10 days after the first dose and with prolonged use (most elevations occurred within 6 to 9 months). Recurrence of liver transaminase elevations may occur with rechallenge. Obtain baseline liver enzymes and bilirubin in all patients prior to therapy initiation (within 6 months) and periodically during therapy and until 2 months after discontinuation of therapy. Monitor liver enzymes and bilirubin in patients who develop symptoms of hepatic injury (eg, right abdominal pain, fatigue, anorexia, jaundice, dark urine). Interrupt treatment if ALT and bilirubin are &gt;3 times and &gt;2 times the ULN, respectively; transaminases tend to return to normal within 2 months of discontinuation. Do not resume treatment if etiology of liver injury cannot be established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Macular edema: Macular edema may occur, typically within the first 6 months of treatment. Patients may present with blurred vision, decreased visual acuity, or without symptoms. Signs and symptoms generally improve or resolve with discontinuation of treatment; however, residual decreased visual acuity has occurred in some patients. Patients with a history of diabetes mellitus or uveitis are at increased risk; use with caution. Ophthalmologic exams (including the fundus and macula) should be performed prior to therapy, 3 to 4 months after treatment initiation, and anytime visual disturbances are reported; more frequent examination is warranted in patients with diabetes or a history of uveitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Cases of lymphoma (eg, non-Hodgkin, CNS, mycosis fungoides) and skin cancers (eg, melanoma, squamous cell carcinoma, Merkel cell carcinoma) have been reported. Basal cell carcinoma and melanoma risk is increased with fingolimod use; monitor for suspicious skin lesions periodically (especially in patients with risk factors for skin cancer) and promptly evaluate. Patients should minimize exposure to sunlight and ultraviolet light by wearing protective clothing and sunscreen with high protection factor.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: Posterior reversible encephalopathy syndrome (PRES) has been observed. Monitor for signs/symptoms of PRES (eg, sudden onset of severe headache, altered mental status, visual disturbances, seizure); symptoms are usually reversible, but may evolve into ischemic stroke or cerebral hemorrhage. Delayed diagnosis and treatment may result in permanent neurological sequelae. Discontinue use if PRES is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Progressive multifocal leukoencephalopathy and associated sequelae: Cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients taking S1P receptor modulators; associated risk factors include use in immunocompromised patients and polytherapy with immunosuppressants. Symptoms progress over days to weeks and may include progressive weakness on one side of the body or clumsiness of limbs, vision disturbances, and mental status changes. Discontinue treatment if PML is confirmed. Immune reconstitution inflammatory syndrome (IRIS) has been reported in patients who discontinued S1P receptor modulator therapy due to developing PML. In most cases, IRIS occurred within a few months after discontinuation. IRIS can result in a decline in patient condition, including characteristic changes on MRI, neurological symptoms, and death; initiate appropriate treatment of inflammation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory effects: Reductions of forced expiratory volume in the first second of expiration (FEV<sub>1</sub>) and diffusion lung capacity for carbon monoxide (DLCO) are dose dependent and may occur within the first month of therapy. FEV<sub>1</sub> changes may be reversible with drug discontinuation. Use in MS patients with compromised respiratory function has not been evaluated. If clinically necessary, spirometric evaluation of respiratory function and evaluation of DLCO should be performed during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: May cause QT prolongation; patients with a prolonged QT interval at baseline (adult and pediatric males: &gt;450 msec; adult females: &gt;470 msec; pediatric females: &gt;460 msec) or during the first 6 hours of treatment initiation, or who are at an increased risk of QT prolongation (eg, hypokalemia, hypomagnesemia, concomitant QT-prolonging drugs [eg, citalopram, chlorpromazine, haloperidol, methadone, erythromycin], congenital long-QT syndrome) require continuous overnight electrocardiogram (ECG) monitoring in a medical facility after the initial dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumefactive multiple sclerosis: MS relapses with tumefactive demyelinating lesions have been reported. May occur at any time during therapy, but most cases occurred within the first 9 months after treatment initiation; may also occur within the first 4 months after treatment discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular: Due to the risk of bradycardia and AV conduction delays, an ECG is required prior to initiation of therapy and after the initial observation period (6 hours) in all patients. Patients receiving concomitant therapy with drugs that slow heart rate or AV conduction (eg, beta-blockers, heart rate-lowering calcium channel blockers, digoxin) or with other cardiac risk factors (eg, AV block, sick sinus syndrome, prolonged QT interval, ischemic cardiac disease, history of myocardial infarction [MI], symptomatic bradycardia and/or cardiac arrest, heart failure, cerebrovascular disease, uncontrolled hypertension, recurrent syncope, severe sleep apnea [untreated]) require continuous overnight ECG monitoring in a medical facility after the first dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use caution in patients with preexisting liver disease; may be at increased risk of increased liver enzymes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings and precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Cases of rebound syndrome (clinical and radiological signs of severe exacerbation beyond what was expected) have been reported; may occur within the first 24 weeks after stopping fingolimod treatment in patients with multiple sclerosis of varying severity and duration. In some cases, relapses have occurred despite the initiation of other disease-modifying therapies. Rebound symptoms have included back and extremity pain, confusion, constipation, diplopia, facial muscle spasms, fatigue, increased leg weakness, nausea paraparesis and paresthesias (Hatcher 2016; Willis 2017). Patients who experience rebound symptoms may not return to the functional status attained during treatment with fingolimod. Monitor for development of IRIS in the setting of PML and severe increase in disability, especially during the first 12 weeks following discontinuation, and begin appropriate treatment as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Patients should complete all immunizations according to current immunization guidelines, if possible, prior to initiating fingolimod therapy. Avoid live-attenuated vaccines in patients who currently receive or have recently discontinued fingolimod; consider using live-attenuated vaccines only if risk of infection is high and killed vaccines are unavailable (AAN [Farez 2019]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878774"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">The safety profile in pediatric patients has been reported as similar to adults; however, pediatric patients have a higher incidence of seizures compared to adults (5.6% vs 0.9%); it is unclear if this is a drug-related or disease-related occurrence.</p></div>
<div class="block foc drugH1Div" id="F10829927"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gilenya: 0.25 mg, 0.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tascenso ODT: 0.25 mg, 0.5 mg</p></div>
<div class="block geq drugH1Div" id="F20452801"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16322867"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Fingolimod HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $350.52 - $370.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Gilenya Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg (per each): $425.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $425.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Tascenso ODT Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg (per each): $416.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $416.92</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871207"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gilenya: 0.25 mg, 0.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg</p></div>
<div class="block admp drugH1Div" id="F52614464"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet: Do not remove tablet from blister pack until ready to administer; peel back foil to expose tablet; do not push tablet through foil. Use dry hands to remove tablet and place immediately on tongue; allow tablet to dissolve before swallowing; may be swallowed with or without water.</p></div>
<div class="block adm drugH1Div" id="F10829909"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet: Do not remove tablet from blister pack until ready to administer; peel back foil to expose tablet; do not push tablet through foil. Use dry hands to remove tablet and place immediately on tongue; allow tablet to dissolve before swallowing; may be swallowed with or without water.</p></div>
<div class="block hazard drugH1Div" id="F49104521"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block sts drugH1Div" id="F10829865"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Protect from moisture. Keep oral disintegrating tablet in sealed blister pack until ready to use.</p></div>
<div class="block meg drugH1Div" id="F10829446"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F022527s038lbl.pdf%23page%3D27&amp;token=fhOpz%2FJswCoAJaFEdgmSEIJKLWAVQObnKwIaXI4X6PxpSqsTXcnaFhi76K0quh0T7arnpO3QICaXVIjwroXK4r7CwVDYtfgEpMvGHMG46JsJdz5DfexTny1%2FzdTfcWwL&amp;TOPIC_ID=118046" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022527s038lbl.pdf#page=27</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53570888"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease (FDA approved in ages ≥10 years and adults).</p></div>
<div class="block cyt drugH1Div" id="F10894405"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor), CYP4F2 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F10890728"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: Fingolimod may enhance the QTc-prolonging effect of Amiodarone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of Fingolimod. Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Fingolimod.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Sphingosine 1-Phosphate (S1P) Receptor Modulator may enhance the immunosuppressive effect of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): Sphingosine 1-Phosphate (S1P) Receptor Modulator may enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): Sphingosine 1-Phosphate (S1P) Receptor Modulator may enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): Sphingosine 1-Phosphate (S1P) Receptor Modulator may enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May increase serum concentrations of the active metabolite(s) of Fingolimod. Ketoconazole (Systemic) may increase the serum concentration of Fingolimod.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the immunosuppressive effect of Sphingosine 1-Phosphate (S1P) Receptor Modulator.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): Fingolimod may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias (including TdP) with a continuous overnight ECG when fingolimod is combined with QT prolonging drugs. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IA Antiarrhythmics (Highest Risk): Fingolimod may enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class III Antiarrhythmics (Highest Risk): Fingolimod may enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Fingolimod may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zoster Vaccine (Live/Attenuated): Fingolimod may enhance the adverse/toxic effect of Zoster Vaccine (Live/Attenuated). The risk of herpes zoster infection may be increased. Fingolimod may diminish the therapeutic effect of Zoster Vaccine (Live/Attenuated).  Management: Wait 1 month after zoster vaccine administration to initiate fingolimod therapy. Avoid the use of the zoster vaccine during fingolimod treatment, and for 2 months following treatment discontinuation.<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49306593"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in females of reproductive potential. Elimination of fingolimod takes approximately 2 months; to avoid potential fetal harm, females of childbearing potential should use effective contraception to avoid pregnancy during therapy and for 2 months after discontinuing treatment.</p>
<p style="text-indent:0em;margin-top:2em;">In general, disease-modifying therapies for multiple sclerosis (MS) are stopped prior to a planned pregnancy except in females at high risk of MS activity (AAN [Rae-Grant 2018]). Consider use of agents other than fingolimod in females at high risk of disease reactivation who are planning a pregnancy. Delaying pregnancy is recommended for females with persistent high disease activity; when disease-modifying therapy is needed in these patients, other agents are preferred (ECTRIMS/EAN [Montalban 2018]). Females who are considering stopping fingolimod when planning pregnancy should be counseled on the possibility of severe worsening of disability. Patients should seek immediate medical attention if they experience new or worsened symptoms of MS after fingolimod is stopped.</p></div>
<div class="block pri drugH1Div" id="F10829508"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome information related to the use of fingolimod in pregnancy is limited (Geissbühler 2018; Karlsson 2014; Lopez-Leon 2020; Navardi 2018; Nguyen 2019; Pauliat 2020). Based on data from animal reproduction studies, in utero exposure to fingolimod may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">In general, disease-modifying therapies for multiple sclerosis (MS) are not initiated during pregnancy, except in females at high risk of MS activity (AAN [Rae-Grant 2018]). When disease-modifying therapy is needed in these patients, agents other than fingolimod are preferred (ECTRIMS/EAN [Montalban 2018]). Clinical rebound (new neurologic symptoms and increased lesions) has been reported when fingolimod treatment was discontinued during pregnancy (Meinl 2018; Novi 2017; Sempere 2013). Females who are considering stopping fingolimod because of pregnancy should be counseled on the possibility of severe worsening of disability. Patients should seek immediate medical attention if they experience new or worsened symptoms of MS after fingolimod is stopped.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to fingolimod is ongoing. Health care providers are encouraged to enroll females exposed during pregnancy in the Gilenya Pregnancy Registry (1-877-598-7237 or https://www.gilenyapregnancyregistry.com). Pregnant females may also enroll themselves.</p></div>
<div class="block mopp drugH1Div" id="F53570887"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">First dose cardiac monitoring: ECG (baseline and at the end of observation period); heart rate, blood pressure, signs and symptoms of bradycardia (hourly for 6 hours following first dose). Continued cardiac observation is required (until resolved, even if asymptomatic) in the following scenarios: If the 6-hour postdose heart rate is lower than the stated values (children 10 or 11 years: &lt;60 bpm; children and adolescents ≥12 years: &lt;55 bpm; adults: &lt;45 bpm); if the 6-hour postdose heart rate is the lowest postdose heart rate (suggesting that maximum heart rate effects have not yet occurred); or if 6-hour postdose ECG shows new-onset second degree or higher atrioventricular block. If postdose symptomatic bradycardia occurs and no pharmacologic treatment is necessary, provide continuous ECG monitoring until symptoms are resolved. If postdose symptomatic bradycardia occurs and pharmacologic intervention is necessary, provide overnight continuous ECG monitoring in a medical facility and repeat the 6-hour observation period for the second dose. Patients also require overnight continuous ECG monitoring in a medical facility if baseline or 6-hour post dose QTc interval is prolonged (&gt;450 msec for pediatric and adult males, &gt;460 msec for pediatric females, &gt;470 msec for adult females), if they have additional risks for QT prolongation (eg, hypokalemia, hypomagnesemia, congenital long-QT syndrome) or if they are receiving concurrent therapy with QT prolonging agents with a known risk of torsades de pointes.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial monitoring procedures (ECG, heart rate, blood pressure) must be repeated in the following situations:</p>
<p style="text-indent:-2em;margin-left:6em;">• Treatment interruption of ≥1 day during the first 2 weeks after treatment initiation</p>
<p style="text-indent:-2em;margin-left:6em;">• Treatment interruption of &gt;7 days during weeks 3 to 4 after treatment initiation</p>
<p style="text-indent:-2em;margin-left:6em;">• Treatment interruption of &gt;14 days after ≥1 month of treatment initiation</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic monitoring: Bilirubin and transaminase levels (baseline [within 6 months of therapy initiation]; at months 1, 3, 6, 9, and 12 of therapy; and periodically thereafter, including for 2 months after therapy discontinuation; immediately in patients who develop symptoms of hepatic dysfunction).</p>
<p style="text-indent:-2em;margin-left:2em;">CBC including lymphocyte counts (baseline, then every 3 months and as clinically necessary) (AAN [Rae-Grant 2018]); latent infection screening (eg, hepatitis, tuberculosis) in high-risk populations or in countries with high tuberculosis burden (baseline); varicella-zoster virus (VZV) antibodies (prior to starting treatment in patients with no health care professional-confirmed history of chickenpox or without documented previous full series VZV vaccination) (AAN [Farez 2019]); signs and symptoms of infection (during treatment and for at least 2 months after discontinuation), progressive multifocal leukoencephalopathy (PML), immune reconstitution inflammatory syndrome (IRIS), and/or posterior reversible encephalopathy syndrome; MRI to monitor for early signs of PML (baseline, periodically, and as clinically indicated); blood pressure and heart rate; ophthalmologic exam at baseline and 3 to 4 months after initiation of treatment (continue periodic examinations for duration of therapy in patients with diabetes, history of uveitis, or visual complaints); respiratory function (FEV<sub>1</sub>, diffusion lung capacity for carbon monoxide [DLCO]) if clinically indicated), skin examination and monitoring for suspicious skin lesions (periodically); severe increase in disability following discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Evaluate pregnancy status prior to use in patients of reproductive potential.</p></div>
<div class="block pha drugH1Div" id="F10829866"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fingolimod-phosphate, a sphingosine-1-phosphate (S1P) receptor modulator and active metabolite of fingolimod, binds to S1P receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks lymphocytes' ability to emerge from lymph nodes, reducing the number of lymphocytes available to the CNS.</p></div>
<div class="block phk drugH1Div" id="F10829868"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~1,200 L: distributes into red blood cells (86%)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99.7% (fingolimod and fingolimod-phosphate)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP4F2 to fingolimod-phosphate (active) and other metabolites (inactive); CYP2D6, 2E1, 3A4, and 4F12 also contribute to metabolism</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 93% </p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 6 to 9 days; prolonged by approximately 50% in patients with moderate or severe hepatic impairment</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 12 to 16 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~81% as inactive metabolites); feces (fingolimod and fingolimod phosphate: &lt;2.5% of dose) </p></div>
<div class="block phksp drugH1Div" id="F51192574"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Fingolimod C<sub>max</sub> and AUC are increased by 32% and 43%, respectively, and by 25% and 14%, respectively, for fingolimod-phosphate in patients with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Fingolimod area under the curve (AUC) increased by 12%, 44%, and 103% in patients with mild, moderate, or severe hepatic impairment, respectively. Fingolimod-phosphate maximal drug concentration (C<sub>max</sub>) was decreased by 22% in patients with severe hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F13276708"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Fegona | Gilenya | Olican | Strilenya</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Biomonar | Emulimod | Fibroneurina | Finglid | Flimor | Gilenya | Gladier | Lebrina | Modina | Mogibe | Vatilen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Chantico | Fingolimod | Fingolimod zentiva | Gilenya</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Gilenya | Pharmacor fingolimod</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod ab | Fingolimod accord | Fingolimod mylan | Gilenya | Inzolfi</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridato de fingolimode | Cloridrato de fingolimode | Gilenya</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod mepha | Fingolimod viatris | Gilenya</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Eminod | Finlim | Gilenya</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aximod ms | Fincler | Finmod | Genbiemod | Gilenya | Iclomod | Lebrina | Limostad | Relsis | Singomod</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod glenmark | Gilenya | Lognif</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Emulimod | Gilenya | Iclomod | Lebrina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod dr reddys | Fingolimod glenmark | Fingolimod mylan | Gilenya | Lognif</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod mylan | Fingolimod ratiopharm | Gilenya | Inzolfi</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod biogaran | Fingolimod mylan | Fingolimod teva | Gilenya</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod accord | Fingolimod glenmark | Fingolimod hydrochloride sandoz | Fingolimod mylan | Fingolimod teva | Fingolimod tillomed | Fingolimod zentiva | Gilenya</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod mylan | Fingolya | Gilenya</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bonaxon | Chantico | Efigalo | Fingolimod pharmascience | Fingolimod q pharm | Fingolimod richter | Fingolimod stada | Gaxenim | Gilenya | Inzolfi | Lognif</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod | Gilenya</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Figo ms | Fingomod</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Gilenya | Melior</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Gilenya | Imusera</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fytarex | Gilenya</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Fegona | Gilenya</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Gilenya | Pms fingolimod | Sclemod</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod mylan | Gilenya</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod mylan | Gilenya</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod accord | Fingolimod glenmark | Fingolimod mylan | Fingolimod teva | Gilenya</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod accord | Fingolimod mylan | Fingolimod teva | Gilenya</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Figoms | Gilenya | Lebrina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Gaxenim | Gilenya</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod | Gilenya</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod generis | Fingolimod stada | Fingolimod teva | Fingolimod zentiva | Gilenya</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod bergamo | Lebrina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod | Fingolimod medisorb | Fingolimod nativ | GILENIA | Gilenya | Modena | Neskler</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Eligon | Fegona | Gilenya | Olican | Sphingolin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod glenmark | Fingolimod mylan | Fingolimod teva | Fingolimod zentiva | Gilenya</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Fingoline | Gilenya</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Findel | Fingomes | Fingya | Finimod | Fondos | Gilenya | Gilomid | Judexa | Vintor</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Gilenya</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Fingolimod vista | GILENIA | Pms fingolimod | Tactrol</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Gilenya | Lebrina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Domilo | Fingolimod alkem | Finkem | Gilenya | Myelenea | Tuvigin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.40">
<a name="USP.40"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29304497">
<a name="29304497"></a>Baharnoori M, Gonzalez CT, Chua A, et al. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. <i>Mult Scler Relat Disord</i>. 2018;20:51-57. doi: 10.1016/j.msard.2017.12.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/29304497/pubmed" id="29304497" target="_blank">29304497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27645336">
<a name="27645336"></a>Bianco A, Patanella AK, Nociti V, et al. Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment. <i>Mult Scler Relat Disord</i>. 2016;9:11-13. doi:10.1016/j.msard.2016.06.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/27645336/pubmed" id="27645336" target="_blank">27645336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34319570">
<a name="34319570"></a>Biolato M, Bianco A, Lucchini M, Gasbarrini A, Mirabella M, Grieco A. The disease-modifying therapies of relapsing-remitting multiple sclerosis and liver injury: a narrative review. <i>CNS Drugs</i>. 2021;35(8):861-880. doi:10.1007/s40263-021-00842-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/34319570/pubmed" id="34319570" target="_blank">34319570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19814729">
<a name="19814729"></a>Brinkmann V, “FTY720 (Fingolimod) in Multiple Sclerosis: Therapeutic Effects in the Immune and the Central Nervous System,” <i>Br J Pharmacol</i>, 2009, 158(5):1173-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/19814729/pubmed" id="19814729" target="_blank">19814729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20061941">
<a name="20061941"></a>Chun J and Hartung HP, “Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis,” <i>Clin Neuropharmacol</i>, 2010, 33(2):91-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/20061941/pubmed" id="20061941" target="_blank">20061941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26308173">
<a name="26308173"></a>David OJ, Pryce M, Meiser K, et al. Pharmacokinetics of fingolimod and metabolites in subjects with severe renal impairment: An open-label, single-dose, parallel-group study. <i>Int J Clin Pharmacol Ther</i>. 2015;53(10):847-854.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/26308173/pubmed" id="26308173" target="_blank">26308173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28954755">
<a name="28954755"></a>Elounais F, Aburahma A, Alkotob ML, Al Hadidi S. Ventricular tachycardia after initiation of fingolimod. <i>BMJ Case Rep</i>. 2017;2017:bcr2017221819. doi:10.1136/bcr-2017-221819<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/28954755/pubmed" id="28954755" target="_blank">28954755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31462584">
<a name="31462584"></a>Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2019;93(13):584-594. doi:10.1212/WNL.0000000000008157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/31462584/pubmed" id="31462584" target="_blank">31462584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Fingolimod (Gilenya). Food and Drug Administration website. <a href="https://www.cdc.gov/niosh/docs/2014-138/pdfs/2014-138.pdf" target="_blank">http://www.fda.gov/Safety/Medwatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm457183.htm</a>. Accessed August 4, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30542374">
<a name="30542374"></a>Geissbühler Y, Vile J, Koren G, et al. Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure. <i>Ther Adv Neurol Disord</i>. 2018;11:1756286418804760. doi: 10.1177/1756286418804760.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/30542374/pubmed" id="30542374" target="_blank">30542374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gilenya.1">
<a name="Gilenya.1"></a>Gilenya (fingolimod) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gilenya.2">
<a name="Gilenya.2"></a>Gilenya (fingolimod) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27135594">
<a name="27135594"></a>Hatcher SE, Waubant E, Nourbakhsh B, et al. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. <i>JAMA Neurol</i>. 2016;73(7): 790-794. doi:10.1001/jamaneurol.2016.0826.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/27135594/pubmed" id="27135594" target="_blank">27135594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28619738">
<a name="28619738"></a>Jasani KM, Sharaf N, Rog D, Aslam T. Fingolimod-associated macular oedema. <i>BMJ Case Rep</i>. 2017;2017:bcr2016218912. doi:10.1136/bcr-2016-218912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/28619738/pubmed" id="28619738" target="_blank">28619738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24463630">
<a name="24463630"></a>Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. <i>Neurology</i>. 2014;82(8):674-680. doi: 10.1212/WNL.0000000000000137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/24463630/pubmed" id="24463630" target="_blank">24463630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29708225">
<a name="29708225"></a>Longbrake EE, Kantor D, Pawate S, et al. Effectiveness of alternative dose fingolimod for multiple sclerosis. <i>Neurol Clin Pract</i>. 2018;8(2):102-107. doi: 10.1212/CPJ.0000000000000434.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/29708225/pubmed" id="29708225" target="_blank">29708225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32444984">
<a name="32444984"></a>Lopez-Leon S, Geissbühler Y, Sabidó M, Turkson M, Wahlich C, Morris JK. A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project. <i>J Neurol</i>. 2020;267(9):2721-2731. doi:10.1007/s00415-020-09913-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/32444984/pubmed" id="32444984" target="_blank">32444984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28920764">
<a name="28920764"></a>Meinl I, Havla J, Hohlfeld R, Kümpfel T. Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis. <i>Mult Scler</i>. 2018;24(7):991-994. doi: 10.1177/1352458517731913.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/28920764/pubmed" id="28920764" target="_blank">28920764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28143860">
<a name="28143860"></a>Memon A, Miranda J. Hepatitis E virus infection in a patient with suspected drug-induced liver injury. <i>BMJ Case Rep</i>. 2017;2017:bcr2016218387. doi:10.1136/bcr-2016-218387<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/28143860/pubmed" id="28143860" target="_blank">28143860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29352526">
<a name="29352526"></a>Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis [published correction appears in <i>Eur J Neurol</i>. 2018;25(3):605]. <i>Eur J Neurol</i>. 2018;25(2):215-237. doi: 10.1111/ene.13536.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/29352526/pubmed" id="29352526" target="_blank">29352526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29474980">
<a name="29474980"></a>Navardi S, Sahraian MA. A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy. <i>Mult Scler Relat Disord</i>. 2018;21:69-70. doi: 10.1016/j.msard.2018.02.015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/29474980/pubmed" id="29474980" target="_blank">29474980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30623864">
<a name="30623864"></a>Nguyen AL, Havrdova EK, Horakova D, et al; MSBase Study Group. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Mult Scler Relat Disord</i>. 2019;28:235-243. doi: 10.1016/j.msard.2019.01.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/30623864/pubmed" id="30623864" target="_blank">30623864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28804745">
<a name="28804745"></a>Novi G, Ghezzi A, Pizzorno M, et al. Dramatic rebounds of MS during pregnancy following fingolimod withdrawal [published correction appears in <i>Neurol Neuroimmunol Neuroinflamm</i>. 2018;5(3):e462]. <i>Neurol Neuroimmunol Neuroinflamm</i>. 2017;4(5):e377. doi:10.1212/NXI.0000000000000377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/28804745/pubmed" id="28804745" target="_blank">28804745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32538681">
<a name="32538681"></a>Pauliat E, Onken M, Weber-Schoendorfer C, et al. Pregnancy outcome following first-trimester exposure to fingolimod: a collaborative ENTIS study. <i>Mult Scler</i>. Published online June 15, 2020. doi:10.1177/1352458520929628<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/32538681/pubmed" id="32538681" target="_blank">32538681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25957334">
<a name="25957334"></a>Pfender N, Jelcic I, Linnebank M, Schwarz U, Martin R. Reactivation of herpesvirus under fingolimod: a case of severe herpes simplex encephalitis. <i>Neurology</i>. 2015;84(23):2377-2378. doi:10.1212/WNL.0000000000001659<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/25957334/pubmed" id="25957334" target="_blank">25957334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35350291">
<a name="35350291"></a>Piñar Morales R, Carrasco Garcia M, Gutierrez-Rojas L, Barrero Hernández FJ. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome after discontinuation of fingolimod. <i>Case Rep Neurol</i>. 2022;14(1):38-43. doi:10.1159/000521944<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/35350291/pubmed" id="35350291" target="_blank">35350291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29686116">
<a name="29686116"></a>Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology [published correction appears in <i>Neurology</i>. 2019;92(2):112]. <i>Neurology</i>. 2018;90(17):777-788. doi: 10.1212/WNL.0000000000005347.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/29686116/pubmed" id="29686116" target="_blank">29686116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28003234">
<a name="28003234"></a>Robinson CL, Guo M. Fingolimod (Gilenya) and melanoma. <i>BMJ Case Rep</i>. 2016;2016:bcr2016217885. doi:10.1136/bcr-2016-217885<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/28003234/pubmed" id="28003234" target="_blank">28003234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23829238">
<a name="23829238"></a>Sempere AP, Berenguer-Ruiz L, Feliu-Rey E. Rebound of disease activity during pregnancy after withdrawal of fingolimod. <i>Eur J Neurol</i>. 2013;20(8):e109-e110. doi: 10.1111/ene.12195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/23829238/pubmed" id="23829238" target="_blank">23829238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26970935">
<a name="26970935"></a>Sharim J, Tashjian R, Golzy N, Pouratian N. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis. <i>J Clin Neurosci</i>. 2016;30:166-168. doi:10.1016/j.jocn.2016.02.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/26970935/pubmed" id="26970935" target="_blank">26970935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tascenso.2">
<a name="Tascenso.2"></a>Tascenso ODT (fingolimod) [prescribing information]. Cambridge, United Kingdom: Cycle Pharmaceuticals Ltd; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26481728">
<a name="26481728"></a>Ueda N, Saida K. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report. <i>BMC Ophthalmol</i>. 2015;15:135. doi:10.1186/s12886-015-0125-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/26481728/pubmed" id="26481728" target="_blank">26481728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25361781">
<a name="25361781"></a>Warnke C, Dehmel T, Ramanujam R, et al. Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. <i>Neurology</i>. 2014;83(23):2153-2157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/25361781/pubmed" id="25361781" target="_blank">25361781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101520">
<a name="28101520"></a>Willis M, Pearson O, Illes Z, et al. An observational study of alemtuzumab following fingolimod for multiple sclerosis. <i>Neurol Neuroimmunol Neuroinflamm. </i>2017;4:e320. doi:10.1212/NXI.0000000000000320.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/28101520/pubmed" id="28101520" target="_blank">28101520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28893804">
<a name="28893804"></a>Yuen HLA, Brown S, Chan N, Grigoriadis G. Immune thrombocytopenic purpura associated with fingolimod. <i>BMJ Case Rep</i>. 2017;2017:bcr2017220590. doi:10.1136/bcr-2017-220590<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fingolimod-pediatric-drug-information/abstract-text/28893804/pubmed" id="28893804" target="_blank">28893804</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 118046 Version 189.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
